On February 12, 2025, Ascendis Pharma A/S announced a plan to use approximately $25 million for a share repurchase program, with up to $18.25 million allocated for buying back American Depositary Shares (ADSs) and $9 million for settling RSU tax obligations, aiming to preserve 200,000 ADSs as treasury shares.